BRKR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 39 cases where BRKR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 67 cases where BRKR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
BRKR moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 200 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BRKR as a result. In 67 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for BRKR turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 32 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
The 10-day moving average for BRKR crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.781) is normal, around the industry mean (2.923). P/E Ratio (-84.436) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.052). Dividend Yield (0.003) settles around the average of (0.009) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRL advanced for three days, in 200 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CRL as a result. In 55 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for CRL just turned positive on October 20, 2026. Looking at past instances where CRL's MACD turned positive, the stock continued to rise in 29 of 48 cases over the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 145 of 228 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
CRL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 2 (best 1 - 100 worst), indicating outstanding price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.798) is normal, around the industry mean (64.450). P/E Ratio (-71.699) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.122) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.340) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
BRKR | CRL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 93 | |
PRICE GROWTH RATING 1..100 | 42 | 2 | |
P/E GROWTH RATING 1..100 | 99 | 85 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (9) in the Medical Specialties industry is in the same range as CRL (15) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to CRL’s over the last 12 months.
BRKR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as CRL (100) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to CRL’s over the last 12 months.
BRKR's SMR Rating (92) in the Medical Specialties industry is in the same range as CRL (93) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to CRL’s over the last 12 months.
CRL's Price Growth Rating (2) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for BRKR (42) in the Medical Specialties industry. This means that CRL’s stock grew somewhat faster than BRKR’s over the last 12 months.
CRL's P/E Growth Rating (85) in the Miscellaneous Commercial Services industry is in the same range as BRKR (99) in the Medical Specialties industry. This means that CRL’s stock grew similarly to BRKR’s over the last 12 months.
| BRKR | CRL | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 68% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 68% |
| Advances ODDS (%) | 2 days ago 69% | 2 days ago 70% |
| Declines ODDS (%) | 9 days ago 74% | 4 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 85% |
| Aroon ODDS (%) | N/A | 2 days ago 64% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while CRL’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 4 TA indicator(s) are bullish while CRL’s TA Score has 4 bullish TA indicator(s).
BRKR (@Medical/Nursing Services) experienced а +6.30% price change this week, while CRL (@Medical Specialties) price change was +14.20% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.66%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +41.88%.
BRKR is expected to report earnings on Nov 02, 2026.
CRL is expected to report earnings on Nov 04, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.66% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To CRL | 1D Price Change % | ||
|---|---|---|---|---|
| CRL | 100% | +9.33% | ||
| IQV - CRL | 71% Closely correlated | +3.28% | ||
| RGEN - CRL | 56% Loosely correlated | +0.63% | ||
| AZTA - CRL | 56% Loosely correlated | +2.88% | ||
| MEDP - CRL | 56% Loosely correlated | +6.43% | ||
| BRKR - CRL | 53% Loosely correlated | +5.68% | ||
More | ||||